304 related articles for article (PubMed ID: 28449207)
1. Targeting anti-apoptotic BCL2 family proteins in haematological malignancies - from pathogenesis to treatment.
Vogler M; Walter HS; Dyer MJS
Br J Haematol; 2017 Aug; 178(3):364-379. PubMed ID: 28449207
[TBL] [Abstract][Full Text] [Related]
2. Targeting BCL2 in Chronic Lymphocytic Leukemia and Other Hematologic Malignancies.
Yalniz FF; Wierda WG
Drugs; 2019 Aug; 79(12):1287-1304. PubMed ID: 31313099
[TBL] [Abstract][Full Text] [Related]
3. BH3 Mimetics in Hematologic Malignancies.
Klener P; Sovilj D; Renesova N; Andera L
Int J Mol Sci; 2021 Sep; 22(18):. PubMed ID: 34576319
[TBL] [Abstract][Full Text] [Related]
4. Therapeutic development and current uses of BCL-2 inhibition.
Roberts AW
Hematology Am Soc Hematol Educ Program; 2020 Dec; 2020(1):1-9. PubMed ID: 33275682
[TBL] [Abstract][Full Text] [Related]
5. Targeting BCL2 With BH3 Mimetics: Basic Science and Clinical Application of Venetoclax in Chronic Lymphocytic Leukemia and Related B Cell Malignancies.
Roberts AW; Huang D
Clin Pharmacol Ther; 2017 Jan; 101(1):89-98. PubMed ID: 27806433
[TBL] [Abstract][Full Text] [Related]
6. Therapeutics targeting Bcl-2 in hematological malignancies.
Ruefli-Brasse A; Reed JC
Biochem J; 2017 Oct; 474(21):3643-3657. PubMed ID: 29061914
[TBL] [Abstract][Full Text] [Related]
7. BCL2 and MCL1 inhibitors for hematologic malignancies.
Roberts AW; Wei AH; Huang DCS
Blood; 2021 Sep; 138(13):1120-1136. PubMed ID: 34320168
[TBL] [Abstract][Full Text] [Related]
8. Targeting BCL2 for the treatment of lymphoid malignancies.
Anderson MA; Huang D; Roberts A
Semin Hematol; 2014 Jul; 51(3):219-27. PubMed ID: 25048785
[TBL] [Abstract][Full Text] [Related]
9. Apoptosis targeted therapies in acute myeloid leukemia: an update.
Ball S; Borthakur G
Expert Rev Hematol; 2020 Dec; 13(12):1373-1386. PubMed ID: 33205684
[No Abstract] [Full Text] [Related]
10. Sonrotoclax overcomes BCL2 G101V mutation-induced venetoclax resistance in preclinical models of hematologic malignancy.
Liu J; Li S; Wang Q; Feng Y; Xing H; Yang X; Guo Y; Guo Y; Sun H; Liu X; Yang S; Mei Z; Zhu Y; Cheng Z; Chen S; Xu M; Zhang W; Wan N; Wang J; Ma Y; Zhang S; Luan X; Xu A; Li L; Wang H; Yang X; Hong Y; Xue H; Yuan X; Hu N; Song X; Wang Z; Liu X; Wang L; Liu Y
Blood; 2024 May; 143(18):1825-1836. PubMed ID: 38211332
[TBL] [Abstract][Full Text] [Related]
11. Enhancing venetoclax activity in hematological malignancies.
Satta T; Grant S
Expert Opin Investig Drugs; 2020 Jul; 29(7):697-708. PubMed ID: 32600066
[TBL] [Abstract][Full Text] [Related]
12. Therapeutic targeting of apoptosis in chronic lymphocytic leukemia.
Ahn IE; Davids MS
Semin Hematol; 2024 Apr; 61(2):109-118. PubMed ID: 38538512
[TBL] [Abstract][Full Text] [Related]
13. Targeting BCL2 with venetoclax is a promising therapeutic strategy for "double-proteinexpression" lymphoma with
Uchida A; Isobe Y; Asano J; Uemura Y; Hoshikawa M; Takagi M; Miura I
Haematologica; 2019 Jul; 104(7):1417-1421. PubMed ID: 30523053
[TBL] [Abstract][Full Text] [Related]
14. The rise of apoptosis: targeting apoptosis in hematologic malignancies.
Valentin R; Grabow S; Davids MS
Blood; 2018 Sep; 132(12):1248-1264. PubMed ID: 30012635
[TBL] [Abstract][Full Text] [Related]
15. Loss in MCL-1 function sensitizes non-Hodgkin's lymphoma cell lines to the BCL-2-selective inhibitor venetoclax (ABT-199).
Phillips DC; Xiao Y; Lam LT; Litvinovich E; Roberts-Rapp L; Souers AJ; Leverson JD
Blood Cancer J; 2015 Nov; 5(11):e368. PubMed ID: 26565405
[TBL] [Abstract][Full Text] [Related]
16. Targeting BCL-2 to enhance vulnerability to therapy in estrogen receptor-positive breast cancer.
Merino D; Lok SW; Visvader JE; Lindeman GJ
Oncogene; 2016 Apr; 35(15):1877-87. PubMed ID: 26257067
[TBL] [Abstract][Full Text] [Related]
17. Clinical experiences with venetoclax and other pro-apoptotic agents in lymphoid malignancies: lessons from monotherapy and chemotherapy combination.
Lew TE; Seymour JF
J Hematol Oncol; 2022 Jun; 15(1):75. PubMed ID: 35659041
[TBL] [Abstract][Full Text] [Related]
18. Therapeutic inhibition of BCL-2 and related family members.
Levy MA; Claxton DF
Expert Opin Investig Drugs; 2017 Mar; 26(3):293-301. PubMed ID: 28161988
[TBL] [Abstract][Full Text] [Related]
19. Found in Translation: How Preclinical Research Is Guiding the Clinical Development of the BCL2-Selective Inhibitor Venetoclax.
Leverson JD; Sampath D; Souers AJ; Rosenberg SH; Fairbrother WJ; Amiot M; Konopleva M; Letai A
Cancer Discov; 2017 Dec; 7(12):1376-1393. PubMed ID: 29146569
[TBL] [Abstract][Full Text] [Related]
20. Potential of BCL2 as a target for chronic lymphocytic leukemia treatment.
Moia R; Diop F; Favini C; Kodipad AA; Gaidano G
Expert Rev Hematol; 2018 May; 11(5):391-402. PubMed ID: 29561706
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
